- CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and…
Dr. Naderi reveals how younger generations are embracing prejuvenation with collagen-boosting treatments and skincare to maintain a natural, youthful glow…
Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technologyDNA delivery technology to be offered as GenePhore™ to biotech…
Key Highlights:Pivot Controller Line Validated: Manufacturing line has now been validated for human-use production in support of expected Q1 2026…
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…
LOS GATOS, CA / ACCESS Newswire / November 3, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a…
Company Extending Warranty as a Promise of Quality and a Thank You to Customers. SALT LAKE CITY, UTAH / ACCESS…
Operators highlight practical levers to speed AI, interoperability, and cyber resilience SAN ANTONIO, TX / ACCESS Newswire / November 3,…
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has…
OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that…